PROGRAM
Wonderful class and very interesting presentations! Quote International Masterclass AMR
Times indicated in Central European Summer Time (CEST)
Program 26 September 2024
The first half-day of the 7th International Masterclass AMR focuses on thoroughly explaining the building blocks of AMR: what are bacteria, what are antibiotics and what is antimicrobial resistance (AMR)? And how can we prevent AMR?
13:30
Welcome and introduction to Antimicrobial resistance (AMR)
Dr Maarten van Dongen, AMR Insights (Netherlands)A closer acquaintance to and demarcation of AMR. How AMR is viewed from different sectors and how we communicate about AMR. How to acknowledge AMR adequately.
14:00
Bacteria: desperately needed and detested
Dr Maarten van Dongen, AMR Insights (Netherlands)What are bacteria, where they occur and how they multiply and spread. What types and subtypes are there and which ones are pathogenic or otherwise harmful. What function do bacteria have, what diseases in humans, animals and plants can they cause and why do we also desperately need bacteria.
14:15
The human Microbiome in health, disease and antibiotic resistance
Dr Maneesh Paul, Microvioma (India)What constitutes the Microbiome and how does it relate to antimicrobial resistance?
14:30
Antibiotics: desperately needed but also cause of AMR
Dr Maarten van Dongen, AMR Insights (Netherlands)What are antibiotics. How they were discovered and how they work. What (classes of) antibiotics there are and how they protect us. And how do they differ. Why and when to use antibiotics and how to appropriately use these in a cost effective way. And when not to use.
14:45
Antibiotics usage in LMICs
Dr Rohini Wadanamby, Lanka hospital (Sri Lanka)How do antibiotics relate to the threat of micro-organisms. What is their added value and when to use. With a focus on LMICs the lecture provides insights into the do’s and don’t related to antibiotics.
15:00
Antibiotic & antimicrobial resistance: the overall picture
Dr Maarten van Dongen, AMR Insights (Netherlands)What are antibiotic resistance and Antimicrobial resistance (AMR). How these develop and spread around the world. Why AMR is increasingly threatening our health and food safety: statistics, socio-economic implications and consequences for public human and animal health. The worldwide increase of a phenomenon that we cannot yet control.
15:15
Bacterial infections and Antimicrobial Resistance in the era of the Covid-19 pandemic
Dr Paula Valle, La Paz Hospital Madrid (Spain)The impact of the ‘visible’ COVID-19 pandemic on the ‘hidden’ AMR pandemic. Results of a retrospective, multi-country analysis.
15:30
The escalating threat of resistant fungi
Dr Jochem Buil, Radboud University Medical Centre (The Netherlands)The fungus Aspergillus fumigatus causes respiratory disorders such as invasive aspergillosis (IA). Medical azoles are effective treatments for Aspergillus disorders, including IA. Azole resistance, primarily produced by fungicide use in the environment, complicates treatment of Aspergillus illnesses significantly. What interests and stakeholders are at stake.
15:45
Driving more AMR innovations towards the clinic: gaps and opportunities in early translation
Dr Peter Coombs, LifeArc (UK)Getting new diagnostics and treatments for AMR to patients is a challenge and consequently the discovery pipeline is currently sparse. There are distinct gaps in accessing the funding and know-how, which could help discovery stage innovation from academics and SMEs progress towards later stage development and downstream investment. How can we address this? And what are the opportunities for harnessing innovation in the early phases of AMR discovery?
16:00
Short break
16:15
The WHO global strategy to combat AMR
Dr Maarten van Dongen, AMR Insights (Netherlands)The WHO Global Action Plan and how National Action Plans must add to the curbing AMR. How WHO, FAO, UNEP and WOAH join forces. The UN and other organisations involved to monitor and control AMR. An overview of the key global stakeholders. The relevance of the UN General Assembly High-Level meeting on AMR (on 26 September, 2024).
16:30
The WHO AWaRe
(Access, Watch, Reserve) antibiotic book
Deborah Tong, World Health Organisation (CH)The 2022 AWaRe book is an important step along the road towards the improved use of antibiotics in humans, the development of stronger AMR policy and better clinical care. Hear about its implementation globally and next steps planned.
16:45
Antibiotic Resistance Surveillance and monitoring AMR
Dr Darcie Carpenter, IHMA (USA)An overview of the current types of ongoing active surveillance programs for monitoring AMR and the strengths and weaknesses of each type.
17:00
AMR in Tuberculosis and Neglected Diseases
Dr. Shridhar Narayanan CEO, Foundation for Neglected Disease Research (India)An overview of tuberculosis and neglected tropical diseases, the emerging drug resistance in these diseases, the need for effective and safer treatments, and the way forward.
17:15
The link between disinfectant resistant bacteria and antibiotic resistant bacteria
Dr Andrew Kemp, British Institute of Cleaning Science (UK)History, problems in understanding the problem of disinfectant resistant bacteria and what ultimately will happen if society ignores the problem and continues to focus only on antibiotic resistance.
17:30
AMR and the AMR Patient: the AMR Narrative Initiative
Dr Renier Coetzee, University of the Western Cape (SA)The purpose of the AMR Narrative is to increase public advocacy ability and involvement in order to mobilize action against antimicrobial resistance.
18:00
Closure Day 1
Hats off to your commitment, courage and persistence on organizing and continuity of these events with such success
Quote International Masterclass AMR
Program 27 September 2024
The second half-day of the International Masterclass AMR focuses entirely on the 6 key strategies to prevent and combat AMR. International AMR experts share their views on how this works and what to expect. To conclude, we will present and discuss the AMR Multi-Stakeholder Partnership Platform and WHO’s strategic research agenda.
13:30
The six key strategies to tackle AMR in the One Health Perspective
Dr Maarten van Dongen, AMR Insights (Netherlands)
13:45
STRATEGY 1: Antibiotic Stewardship and knowledge sharing as a force for tackling AMR
Dr David Jenkins, Consultant Medical Microbiologist University Hospitals of Leicester NHS Trust and former President BSAC (UK)Monitoring and limiting the use of antibiotics reduces the risk of AMR. How this can be implemented in human health care: feasibility in HIC and LMICs alike. The potential of stewardship to diminish AMR, the relevance of knowledge sharing and the role of the newly set up GASPh. The recent launch of the BSAC Global Antimicrobial Stewardship Accreditation Scheme (GAMSAS).
14:15
STRATEGY 1 (continued): Challenges and further steps in Antimicrobial Stewardship in LMICs
Dr Ruba Haddadin, AMS Advisor (Jordan)Implementing AMS initiatives in low—and Middle-Income Countries (LMICs) faces significant challenges that hinder their effectiveness. Further steps are needed to strengthen these efforts. By addressing these challenges, building on existing initiatives, and supporting the vital next steps required to enhance AMS efforts in these regions, LMICs can make significant progress.
14:30
STRATEGY 2: Microbial Diagnostics and new technologies to reach the market
Prof Till Bachmann; University of Edinburgh, Edinburgh (UK)Diagnostics help us to set the proper patient treatment. Diagnostics distinguish bacteria from viruses, identify bacterial species (ID) and determine the antibiotics sensitivity (AST). Do we use diagnostics properly and do we use the proper diagnostics. Emerging scientific developments in diagnostics and what new diagnostic tools may reach the market.
15:00
STRATEGY 3: Novel Antibiotics and the context of the broken market
Usha Lamichhane; Global AMR R&D Hub (Germany)New antibiotics, to which bacteria are still sensitive, are increasingly needed in the global fight against AMR. Why only very few new antibiotics appear on the market. Challenges related to antimicrobial R&D, the lack of funding and a proper return of investment for pharma companies. Upcoming market push and market pull mechanisms in the UK and the USA. The important roles played by CARB-X, GARDP, AMR Industry Alliance and AMR Action Fund. All this in the perspective of the Global AMR R&D Hub.
15:30
STRATEGY 3 (continued): Incentivizing investment into antibiotic R&D – what is needed?
James Anderson, Executive Director, Global Health, IFPMA (Switzerland)We desperately need new antibiotics, yet innovation in this space is faltering due to unique market challenges faced by these life-saving drugs. The clinical pipeline is dangerously thin and without new investment, AMR burden will continue to rise, threatening modern medicine. Perspectives on possible solutions and policy needs from the pharmaceutical industry.
15:45
STRATEGY 4: Infection Prevention and Control and the key role of vaccination
Prof Adam Cunningham; University of Birmingham and Co-Director Bactivac (UK)Infection prevention results in the decreased use of antibiotics and prevents (resistant) bacteria from spreading. The impact of vaccination of humans and animals (in addition to good sanitation, hygiene and use of disinfectants) to prevent AMR. The impact of the global bacterial vaccinology network BactiVac to accelerate the development of vaccines relevant to LMICs.
16:15
STRATEGY 5: How much is possible to find alternatives to antibiotics?
Prof Jayaseelan Murugaiyan; SRM University AP (India)Alternatives to antibiotics are increasingly important to curb AMR. In addition to phage therapy, antimicrobial tissue replacers, nanomaterials and probiotics appear to fight (resistant) bacteria without leading to AMR. What are the developments and what are the promises in theory and practice. A unique, structured overview of all alternatives and where they can be used.
16:45
STRATEGY 6: Reducing Antibiotic Emissions in waste water
Steve Brooks, President Steve Brooks Consulting LLC (USA), Joseph Muratore and Lisa Lowe, BSI Group (UK)Steve currently serves as an Advisor to the Antimicrobial Resistance (AMR) Industry Alliance, and chairs the Manufacturing Work Group of the Alliance. Steve will present the environmental dimensions of AMR recognized as part of the “One Health” approach to addressing AMR. Antibiotics that enter the aquatic environment, eg from animal and human use and excretion, from antibiotic manufacturing waste water, may present a risk of resistance developing in environmental bacteria unless adequately controlled. In this session The AMR Industry Alliance will describe its work with the British Standards Institution (BSI) to develop antibiotic manufacturing standard (establishing adequate control) and an accompanying certification scheme that provides independent verification that an antibiotic is made in accordance with the standard. The BSI Kitemark for Minimized Risk of AMR certification is a distinguished program aimed at mitigating the threat of antimicrobial resistance (AMR) through environmental controls. It confirms that antibiotic manufacturers effectively manage and reduce the environmental impact of antibiotic waste discharge. Joseph will explain the certification value and the drivers for adoption. Lisa will follow by providing the technical view of what needs to be ready for the assessment.
17:15
STRATEGY 6 (continued): Hospital waste water and AMR
Tom Vereijken, Director European Water Stewardship (Netherlands) and Dr Tania Mubita, Expertise Leader Wageningen University and Research (Netherlands)Tom will introduce the Dutch Consortium Antibiotics and Pharmaceutical Residues from Water and the white paper on AMR and waste water drafted by the consortium. Tania will explain the status and expected outcome of the Dutch research and development project ‘Onsite Monitoring and Removal of Pharmaceuticals, Antibiotics, and Antimicrobial Resistance at Source’.
17:30
AMR Multi-Stakeholder Partnership Platform
Nelea Motriuc, Coordinator, AMR Multi-Stakeholder Partnership Platform (CH)The AMR Multi-Stakeholder Partnership Platform is a global, collaborative, and inclusive mechanism that aims to catalyze a global movement for action against AMR by stakeholders from the One Health sectors (human, animal, agriculture, plant, environment). Established in November 2022 by the Quadripartite (FAO, UNEP, WHO and WOAH) following the recommendation of the 2019 IACG report, the Platform aims to promote a shared global vision on AMR and build stakeholder consensus to assist in preserving antimicrobials as lifesaving medicines and ensuring their responsible use under a One Health approach.
17:45
Quadripartite One Health AMR tools and Guidance to support countries in the implementation of NAPs
Jorge Matheu, Team Lead, AMR Division, WHO (CH)The Quadripartite organizations (FAO, UNEP, WHO, and WOAH) have developed tools and guidance to address AMR in the One Health scenario, the WHO Medically Important Antimicrobial list guides countries to increase the responsible use of antimicrobials in non-human sectors. The QPT Guidance on One Health Integrated Surveillance of AMR/AMU will guide countries in establishing national integrated surveillance and collecting data on AMR/AMU with an integrated analysis to develop interventions to contain AMR. The One Health Priority Research Agenda for AMR report is a joint initiative to assist in directing and catalyzing scientific interest and financial investments for the priority research agenda across sectors for countries and funding bodies. The One Health Legislative Assessment tool on AMR provides countries guidance to identify legislative gaps in AMR and work to improve the legislation to strengthen the governance in the implementation of the NAPs.
18:00
Closure Day 2
Dr Maarten van DongenThanks to all the panellists! Such an inspiring masterclass
Quote International Masterclass AMR
